ABSTRACT
Large-scale brain network function is critical for healthy cognition, yet links between such network function, neurochemistry, and smaller-scale neurocircuitry are unclear. Here, we evaluated 59 healthy individuals using resting-state fMRI to determine how network-level temporal dynamics were impacted by two well-characterized pharmacotherapies targeting catecholamines: methylphenidate (20mg) and haloperidol (2mg). Network dynamic changes were tested for links with drug-induced alterations in complex corticostriatal connections as this circuit is a primary site of action for both drugs. A randomized, double-blind, placebo-controlled design was used. Methylphenidate enhanced time spent in the default mode network (DMN p<0 .001) and dorsal attention network (DAN p<0.001) and reduced time in the frontoparietal network (p<0.01). Haloperidol increased time in a sensory motor-DMN state (p<0.01). The magnitude of change in network dynamics induced by methylphenidate vs. placebo was correlated with the magnitude of methylphenidate-induced rearrangement of complex corticostriatal connectivity (R=0.32, p=0.014). Haloperidol did not alter complex corticostriatal connectivity. Methylphenidate increased time in networks involved in internal (DMN) and external attention (DAN), aligning with methylphenidate’s established role in attention. Methylphenidate also significantly changed complex corticostriatal connectivity by altering the relative strength between multiple corticostriatal connections, indicating that methylphenidate may shift which corticostriatal connections are prioritized relative to others. Findings further show that these local circuit changes are linked with large scale network function. Collectively, these findings provide a deeper understanding of large-scale network function, set a stage for mechanistic understanding of network engagement, and provide needed information to potentially guide medication use based on network-level effects.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01924468
Funding Statement
This work was supported by the National Institute on Drug Abuse Intramural Research Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board of the National Institutes of Health gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is not currently available for this data set but may become so upon reasonable request and regulatory approval.
